Arcus Biosciences finds itself at the edge of a familiar biotech precipice: a company whose future has narrowed to a single compound, a single bet, and a shrinking window of time. In the second quarter of 2026, revenue fell 74% year-over-year to $41 million while losses deepened, prompting the company to cut its full-year guidance to between $65 and $75 million. The story unfolding in Echo Harbor's economy is an old one dressed in new urgency — the distance between scientific promise and financial survival is measured not in years, but in the next clinical readout.